Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial
Authors:
- Eva Mmed NatukundaENEva Mmed Natukunda
- Alex J. Msc SzubertASAlex J. Msc Szubert
- Mutsa Bwakura-DangarembiziMBMutsa Bwakura-Dangarembizi
- Veronica Msc MulengaVMVeronica Msc Mulenga
- Katja DoerholtKDKatja Doerholt
- Abbas Msc LugemwaALAbbas Msc Lugemwa
- Spencer Bsc ByaruhangaSBSpencer Bsc Byaruhanga
- Esther Msc NambiENEsther Msc Nambi
- Diana M. GibbDGDiana M. Gibb
- Grace NdeeziGNGrace Ndeezi
- 24 February 2026
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (9) , 768-775
Abstract
Background: Few studies have compared body composition changes in children living with HIV receiving integrase inhibitors or boosted protease inhibitors. Methods: Children switching to second-line antiretroviral therapy were randomized to dolutegravir (DTG), darunavir/ritonavir (DRV/r), atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r), and to tenofovir alafenamide (TAF) or standard of care (abacavir or zidovudine) using a factorial design. Body composition was measured using bioelectric impedance analysis over 96 weeks. Associations between baseline characteristics and changes in fat mass, fat-free mass, muscle mass and body fat percentage were estimated using robust regression with multivariable fractional polynomial selection (exit P = 0.05). Results: Eight hundred forty-one participants were included in the analysis. Females compared with males had greater fat accrual (+4.66% body fat, +1.32 kg fat mass; both P < 0.001). Compared with LPV/r, ATV/r and DTG exposures were associated with higher fat-free mass [+0.85 kg (95% confidence interval: 0.43–1.27) and +0.79 kg (0.37–1.21) respectively] and muscle mass [+0.82 kg (0.41–1.23) and +0.82 kg (0.42–1.22), respectively] (all P < 0.001). TAF and DRV/r exposures were associated with higher fat mass [+0.32 kg (0.12–0.52) P = 0.002; +0.33 kg (0.04–0.61) P = 0.025, respectively]. Prior nevirapine exposure was also associated with greater fat accrual [+0.36 kg (0.13–0.58) vs. efavirenz, P = 0.002]. Baseline CD4 and viral load, time on first-line antiretroviral therapy, and site were also associated with composition changes. Conclusions: DTG and ATV/r were associated with greater gains in fat-free mass and muscle mass than LPV/r, while DRV/r, TAF and prior nevirapine exposure were associated with fat mass accrual. Fat gain may initially reflect return to health but sustained increases may have metabolic implications. These findings suggest the need to monitor fat compartments with long-term exposure.Keywords
This publication has 29 references indexed in Scilit:
- Second-Line Antiretroviral Therapy for Children Living with HIV in AfricaNew England Journal of Medicine, 2025
- Cardiovascular disease and its risk factors among people living with HIV: A systematic review and meta-analysisJournal of Infection and Public Health, 2025
- Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohortsJournal of the International AIDS Society, 2024
- Associations of linear growth with body composition of perinatally HIV-infected African adolescentsBritish Journal of Nutrition, 2024
- Weight gain during the dolutegravir transition in the African Cohort StudyJournal of the International AIDS Society, 2022
- Changes in central adipose tissue after switching to integrase inhibitorsHIV Research & Clinical Practice, 2021
- Growth in HIV-1-exposed but uninfected infants treated with lopinavir–ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trialThe Lancet HIV, 2019
- LMS tables for waist-circumference and waist-height ratio Z-scores in children aged 5–19 y in NHANES III: association with cardio-metabolic risksPediatric Research, 2015
- Lopinavir impairs protein synthesis and induces eEF2 phosphorylation via the activation of AMP‐activated protein kinaseJournal of Cellular Biochemistry, 2008
- CD4+ Cell Count, Viral Load, and Highly Active Antiretroviral Therapy Use Are Independent Predictors of Body Composition Alterations in HIV-Infected Adults: A Longitudinal StudyClinical Infectious Diseases, 2005